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1. Introduction  
Drug abuse and dependence disorders are chronic but treatable brain diseases, involving 
compulsive drug-seeking and -using behaviors that persist despite immediate or potentially 
harmful consequences for users and their families and communities. Drug abuse and 
dependence are serious threats to public health and safety, costing hundreds of billions of 
dollars in yearly healthcare expenditures, crime, poor work productivity, and job loss 
(Hoffman & Fromeke, 2007). For example, illegal drug use in the United States cost nearly 
200 billion dollars in 2002; approximately two-thirds of the costs (129 billion) were economic 
losses attributable to people’s inability to work because of drug-precipitated illness, 
premature death, or incarceration. The treatment of the healthcare problems of drug addicts 
cost 16 billion dollars, while drug-related criminal justice and welfare costs totaled 36 billion 
dollars in 2002 (Office of National Drug Control Policy, 2004). Addiction also can result in 
intangible costs, such as homelessness, academic failure, and troubled relationships, and is 
one of the most pervasive and intransigent mental health disorders in the world, affecting 
the thoughts, feelings, and behaviors of millions of people annually (World Health 
Organization, 2004).  
2. Drug effects and classification 
Drugs are psychoactive substances that change moods and behaviors by altering brain 
chemistry and function (Hyman & Malenka, 2001). Drugs of abuse include medically 
prescribed (e.g., barbiturates and pain relievers), legal (e.g., alcohol and nicotine), and illegal 
(e.g., marijuana and heroin) substances. Some drugs, such as alcohol, have been used since 
ancient times, whereas others, such as methamphetamine and designer drugs (e.g., Ecstasy), 
are relatively new. People consume drugs to feel good (some drugs produce euphoria, 
confidence, and relaxation), to keep from feeling bad (some drugs combat anxiety, 
depression, and hopelessness), to accelerate performance (some drugs sharpen attention and 
enhance physical strength and athletic prowess), and to experience altered sensory 
perceptions (some drugs cause visual, auditory, or tactile hallucinations) (National Institute 
on Drug Abuse [NIDA], 2007).  
Drugs of abuse can be classified into five groups according to effects. The first class consists 
of stimulants, which increase alertness and decrease fatigue; examples include 
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amphetamines, Benzedrine, caffeine, Dexedrine, ephedrine, and nicotine. The second class 
consists of depressants, which reduce tension, alleviate nervousness, and induce sedation. 
Among these drugs are Nembutal, Seconal, Tunial, Veronal, Valium, and Xanax. The third 
class, hallucinogens, changes sensory perceptions; examples include cannabis, Lysergic Acid 
Diethylamide (LSD), Mescaline, Phencyclidine (PCP), and psilocybin. The fourth class 
consists of opiates, which induce sleep, euphoria, and relaxation as well as relieve pain and 
anxiety; opiates include codeine, heroin, opium, OxyContin, Percodan, and morphine. The 
fifth class consists of performance enhancers; they increase athletic strength and speed and 
stimulate the growth and recovery of skeletal muscles. Anadrol, Depo-Testosterone, 
Dianabol, and Winstrol are some examples of such performance enhancers (Abadinsky, 
2007).       
Drug abusers typically prefer one class of drugs over others. However, when they have 
difficulty obtaining their drug of choice, they often turn to other drugs in the same class that 
produce similar effects. Psychoactive drugs in the same class can be compared on the basis 
of their potency and efficacy. The potency of a drug is the amount that must be ingested to 
produce a desired effect whereas efficacy is a drug’s ability to produce a desired effect 
regardless of dosage. Both the strength and the potency of a substance can determine an 
abuser’s drug of choice as well as the drug’s potential for abuse and dependence (see below) 
(NIDA, 2007).  
3. The addictive process  
Drug use can escalate to substance use disorders: abuse or dependence. The progression to 
uncontrolled use depends on several risk factors. For example, biological factors play a role 
in addiction; in other words, genetics can predispose a person to addictive behavior—a 
predisposition that is shared among close biological relatives. Scientists estimate that genes 
account for nearly half of a person’s vulnerability to a substance use disorder (NIDA, 2007). 
Age of first use and psychiatric history are also important factors for explaining drug use 
problems. Younger users are more likely to become addicted because developing adolescent 
brains are more susceptible to a drug’s ability to change brain chemistry and functions. 
Likewise, people with mental illness are also more likely to abuse or become dependent on 
drugs. In addition, a person’s exposure to a parent’s or a peer’s use of drugs can increase his 
or her risk of addiction. The mode of drug ingestion can also raise the potential for abuse 
and dependence: a drug that is inhaled or injected is more addictive than one that is 
ingested orally. Inhalation and injection send the drug to the brain faster and produce more 
intense highs and lows. Drug-seeking behavior intensifies in response to the cycle of peaks 
and valleys that the user experiences (Hoffman & Fromeke, 2007).  
Psychoactive drugs are thought to become addictive through their activation of the brain’s 
mesocorticolimbic dopamine pathway, extending from the brain’s ventral tegmental area to 
the nucleus accumbens to the frontal cortex. Drugs of abuse stimulate this pleasure circuit 
by increasing the amount of dopamine in the brain two- to ten-fold, creating an extremely 
pleasurable experience for users that compels them to repeat the incident. Drugs of abuse 
either mimic the effects of dopamine on neurotransmitters (i.e., they act as agonists) or block 
the re-absorption of dopamine so that it can continue to activate neurons (i.e., they act as 
antagonists). Eventually, the brain shuts down its own production of dopamine, causing the 
user to ingest the drug merely to stave off feelings of listlessness, depression, and other 
withdrawal symptoms. Drugs of abuse also affect the brain’s frontal regions, impairing 
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judgment and leading addicts to crave drugs even as the rewards of use steadily diminish. 
Hence, relapses—a return to drug use after a period of abstinence—are common among 
people with substance use disorders and can be triggered by stress, mood changes, and cues 
that remind the abuser of the substance (Karch, 2007; NIDA, 2007).                 
4. Substance use disorders  
Substance abuse and dependence disorders are diagnosed according to criteria in the 
American Psychiatric Association’s Diagnostic and Statistical Manual IV-TR (American 
Psychiatric Association, 2007). A substance abuse disorder is diagnosed when drug use in 
the previous 12 months has led to significant distress and impairment in functioning and 
meets at least one of several diagnostic criteria—namely, failure to fulfill obligations at 
work, school, or home; recurring use of substances in dangerous situations (e.g., driving 
while intoxicated); recurring substance use-related criminal justice involvement; and 
continued substance use that leads to interpersonal conflicts.  
A drug-dependence disorder—more serious than a drug-abuse disorder—is diagnosed 
when drug use in the previous 12 months has reached the level of abuse and meets at least 
three of seven criteria that include tolerance (i.e., increasing amounts of the drug must be 
taken to achieve desired effects), physical withdrawal (i.e., symptoms that accompany the 
cessation of drug use, such as tremors, chills, drug craving, restlessness, bone and muscle 
pain, sweating, and vomiting), and persistent failure to reduce drug consumption.  
5. Prevalence of drug use and substance use disorders  
The National Survey on Drug Use and Health assesses the prevalence of substance use and 
substance use disorders in the United States. In 2005, an estimated 20 million Americans age 
12 or older (or 8 percent of the total population in this age group) reported having used an 
illicit substance in the previous month; marijuana was the most commonly used drug (15 
million), followed by cocaine (2 million), hallucinogens (1 million), methamphetamine 
(580,000), and heroin (166,000). Meanwhile, an estimated 22 million people age 12 or older 
were classified with a substance abuse or dependence problem (9 percent of the population). 
Among them, more than 3 million were classified with abuse of or dependence on both 
alcohol and illicit drugs; more than 3.5 million had abused or were dependent on illicit 
drugs but not alcohol; and more than 15 million had abused or were dependent on alcohol 
but not illicit drugs (Substance Abuse and Mental Health Services Administration, 2007).   
In 2005, the order of lifetime illicit drug use among members of the general population 
paralleled past-month illicit drug use in 2005. Nearly half (46 percent) of people age 12 or 
older reported the lifetime use of any illicit substance. The most popular drug was 
marijuana (40 percent), followed by powder or crack cocaine (17 percent), hallucinogens (14 
percent), methamphetamine (4 percent), and heroin (2 percent).    
6. A public health approach to addiction 
The most widely used definition of health is found in the World Health Organization’s 
(WHO) 1948 charter: “Health is a state of complete physical, mental, and social well-being 
and not merely the absence of disease or infirmity.” This definition was expanded by the 
WHO in its 1986 Ottawa Charter for Health Promotion in order to underscore the notion that 
www.intechopen.com
 
Psychiatric Disorders – Trends and Developments 
 
322 
health is “a resource for everyday life, not the objective of living. Health is a positive concept 
emphasizing social and personal resources as well as physical capacities” (WHO, 1986, p. 
11). By this definition, drug addiction is a serious public health problem that adversely 
affects all of these domains. As I have discussed in this chapter, drug abuse and dependence 
are formidable threats to public health and safety, costing hundreds of billions of dollars in 
yearly healthcare expenditures, crime, poor work productivity, and job loss (Hoffman & 
Fromeke, 2007; United Nations Office on Drugs and Crime, 2006).  Treating addiction as a 
crime rather than a health problem compounds its negative impact on individuals and 
communities in terms of public health and safety. Not only do most addicted ex-offenders 
emerge from behind bars with untreated substance use disorders, but they are likely to have 
been exposed to a variety of contagious diseases in prison, to have learned criminogenic 
behaviors that discourage contributive citizenship, and to have lost connections with family 
and friends whose support is critical for their healthy reintegration into society.  
7. Importance of treatment 
Prevention and education programs for nonusers and treatment programs for users are 
widely recognized as the most effective means of decreasing the demand for drugs. 
However, throughout the long history of the drug war, approximately two-thirds of 
government expenditures have been on supply reduction efforts. Numerous experts 
acknowledge that supply-side interventions have done little to curtail drug use or the 
violence that accompanies the sale and distribution of illegal drugs in the United States 
(MacCoun & Reuter, 2001). Moreover as I noted above, prohibition and strict penalties for 
drug possession and sales have spawned many unanticipated problems. Nonetheless, few 
government officials are willing to shift the emphasis of the war on drugs away from 
punitive measures and toward treatment and rehabilitation programs for people with 
substance use disorders. Most politicians are particularly reluctant to decry punitive drug 
policies out of fear of being labeled as “soft on crime” and losing the support of their 
constituents (Kleinman, 1992; Nadelmann, 1989). 
Offenders with drug use problems are a diverse group, and the relationship between drugs 
and crime is complicated (Bureau of Justice Statistics, 1991). Offenders become addicted to 
drugs and commit crimes as a result of various events in their lives (Lurigio & Swartz, 1999). 
Whatever the road to addiction and criminality, drug control policies must fully incorporate 
what research has consistently shown: drug addiction is a chronic relapsing brain disease 
with biological, psychological, social, and behavioral concomitants. Therefore, programs for 
drug-abusing offenders should be comprehensive and include a wide range of treatment 
and adjunctive social services (Gerstein & Harwood, 1990). 
One of the most successful examples of drug treatment as an alternative to incarceration has 
been Arizona’s Proposition 200, the Drug Medicalization, Prevention and Control Act of 
1996. This initiative prohibits incarceration for first- and second-time non-violent drug 
offenders, mandating probation and drug treatment instead of prison. A 1999 evaluation of 
the initiative by the Arizona Supreme Court found that it saved taxpayers 2.6 million dollars 
annually. Furthermore, nearly 75% of the drug offenders who had been sentenced to 
probation and drug treatment as a result of Proposition 200 remained drug-free during their 
participation in the program and paid their own money to offset the cost of treatment 
(Arizona Supreme Court, 1999).  
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A similar initiative in California has also significantly reduced incarceration rates and criminal 
justice expenditures. California’s Proposition 36, the Substance Abuse and Crime Prevention 
Act (SACPA), allows first- and second-time non-violent drug offenders to enter substance 
abuse treatment programs as opposed to being incarcerated. Although the impact of SACPA 
varied by county based on the characteristics of drug treatment programs (in-patient vs. 
outpatient, duration of treatment), results showed that after 5 years, SACPA reduced the 
prison population of those convicted of drug possession by 27%. This resulted in an estimated 
savings of $350 million in prison costs alone (Ehlers & Ziedenberg, 2006). The costs associated 
with arrests and convictions were also significantly lower among drug offenders who 
completed treatment, compared to those who never entered treatment and those who entered 
but did not complete treatment (Longshore, Hawken, Urada, & Anglin, 2006). California saved 
more than $2.50 for every dollar spent on drug treatment; for those who completed treatment, 
the savings increased to $4 saved for every dollar spent (UCLA, 2007).  
Studies of substance abuse treatment for drug offenders have repeatedly demonstrated the 
success of these programs in reducing drug use and its attendant problems, as well as in 
significantly decreasing the costs associated with crime and the criminal justice system. 
Drug treatment programs have proven effective as an alternative to incarceration and as a 
prison-based, post-release, or work-release intervention for addicted offenders. Hence, drug 
treatment is suitable for a wide range of offenders, and it is a cost-effective intervention at 
various points in the criminal justice process. 
Considerable research shows the crime-reducing benefits and cost effectiveness of treatment 
relative to other antidrug measures (e.g., interdiction) and supports a greater investment in 
drug treatment (Anglin & Hser, 1990). Nonetheless, the treatment infrastructure in the 
criminal justice system has eroded over the past several years, a disheartening development 
that bodes ill for future efforts to control crime and reduce illegal drug use (Lipton, 1995). 
For example, despite record numbers of people incarcerated for drug crimes, the proportion 
of drug offenders who received drug treatment in prison declined throughout the 1990s and 
remained at a low level during the early 2000s (Belenko, Patapis, & French, 2005; Inciardi, 
1996). 
The economic benefits of drug treatment accrue mostly from reductions in incarceration, 
criminal victimization, medical treatment, and lost wages (Hoffman & Fromeke, 2007). A 
recent study in California found that the state saved $7,500 in aggregate reductions in crime 
and incarceration for every addicted person treated (Ettner, Huang, Evans, Ash, Hardy, 
Jourabchi, & Hser, 2007). A similar study found that every dollar spent on drug treatment 
resulted in an average savings of seven dollars, stemming from decreased crime and its 
corollaries (e.g., increased employment and major reductions in healthcare expenditures) 
(McCarthy, 2007). In an extensive review of hundreds of studies of drug treatment 
programs, Belenko, Patapis, and French (2005) found that drug treatment reduces drug use 
and crime, incarceration, and victimization as well as health care expenses and other 
medical costs. Belenko et al. (2005) concluded that “it is clear from research on the economic 
impacts of substance abuse addictions on health, crime, social stability, and community 
well-being that the costs to society of not (authors’ italics) treating persons with substance 
abuse problems would be quite substantial” (p. 58).  
8. Types of drug treatment: A brief overview 
As I mentioned previously in this chapter, addiction is a recurring disease that often 
requires repeated episodes of treatment. The ultimate goal of treatment is sustained 
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abstinence. During the process of recovery, treatment is designed to improve overall 
functioning while minimizing the social and medical consequences of substance abuse and 
dependence disorders. The recovery process begins with treatment and progresses as 
addicts gain insights into their uncontrolled use of alcohol and drugs and start to manage 
their thoughts, feelings, and behaviors (Center for Health and Justice, 2006).  
The course of treatment for drug-dependent persons follows a general therapeutic process 
and lies on a continuum of care (NIDA, 2006b). Drug treatment  encompasses a broad range 
of services, including detoxification, educational and vocational training, urine testing, 
counseling, HIV education and prevention, life and interpersonal skills training, psychiatric 
care, pharmacotherapy, psychotherapy, relapse prevention strategies, and self-help groups 
(see section on drug treatment principles below) (Anglin & Hser, 1990; Hoffman & Fromeke, 
2007; Peters, 1993). Depending on the nature and severity of the addiction and an 
individual’s progress toward recovery, treatment can occur at various levels and in diverse 
settings: inpatient, intensive outpatient, outpatient, or sobriety maintenance (Center for 
Health and Justice, 2006). NIDA (2006b) classifies treatment into two broad categories: 
pharmacological and behavioral. 
The use of medication in recovery typically begins during detoxification. Persons who are 
physically dependent on alcohol and drugs are placed on medications to safely alleviate the 
painful symptoms and control the adverse physical consequences of withdrawal. 
Medication is used in the treatment and relapse prevention process to “help re-establish 
normal brain function and to prevent relapse and diminish [drug] cravings” (NIDA, 2006b, 
p. 3). For example, buprenorphine and methadone effectively treat opiate addiction by 
blocking withdrawal symptoms and reducing drug cravings. The passage of the Drug 
Addiction Treatment Act in 2000, permits physicians to prescribe these medications in 
medical settings; previously, such medications could be dispensed only in specialized drug 
treatment clinics. Promising new medications for drug addiction are pending FDA 
approval, including Baclofen (for cocaine addiction), Nalemfene (for opiate addiction), 
Topitamate (for alcohol, opiate, and cocaine addiction), and Disulfiram (for cocaine 
addiction [although for many years used for alcohol addiction]) (Hoffman & Fromeke, 
2007).    
Behavioral therapy consists of interventions designed to change addicts’ attitudes and 
behaviors as well as help them acquire the skills and competencies they need to avoid 
relapses. Several behavioral approaches have proved successful in treating addicts—used by 
themselves or in combination with medications. The most common are cognitive behavioral 
therapy (helps addicts avoid relapse triggers), multidimensional family therapy (focuses on 
adolescents and their peers and family members), motivational enhancement therapy 
(capitalizes on addicts’ readiness to change their behaviors and begin treatment), and 
motivational incentive therapy (employs positive reinforcement and contingency 
management techniques to promote abstinence) (NIDA, 2006b).             
9. Drug treatment studies 
Abundant research demonstrates that drug treatment reduces illegal drug use, crime, and 
recidivism in the general and correctional population (Anglin & Hser, 1990; Anglin et al., 
1996; Gerstein & Harwood, 1990; Office of Technology Assessment, 1990). Since the 1960s, 
numerous studies at the local, state, and federal levels have shown that drug treatment 
works (Lurigio, 2000). The best research on drug treatment consists of large-scale, 
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federally funded studies that involve large samples of participants and employ 
longitudinal designs and a comprehensive range of outcome measures. These studies 
have provided the most compelling evidence that addiction is a treatable disease and 
have identified the principles of drug treatment that characterize the most useful and 
effective programs (see below).   
10. Large-scale studies of drug treatment 
Three large-scale, multisite investigations, funded by NIDA, strongly support the conclusion 
that drug treatment works: the Drug Abuse Reporting Program (DARP), the Treatment 
Outcome Prospective Study (TOPS), and the Drug Abuse Treatment Outcome Study 
(DATOS). These evaluations of community-based treatment have contributed greatly to our 
knowledge about the benefits of drug treatment and significantly influenced drug treatment 
policies, programs, and research (Gerstein & Harwood, 1990; McLellan, Metzger; Alterman, 
Cornish, & Urschel, 1992; Simpson, Chatham, & Brown, 1995). As Lillie-Blanton (1998) 
stated, "these studies are generally considered by the research community to be the major 
evaluations of drug abuse treatment effectiveness, and much of what is known about 
'typical' drug abuse treatment outcomes comes from these studies" (p. 3). 
10.1 Drug abuse reporting program 
DARP involved more than 44,000 persons admitted to drug treatment between 1969 and 
1973. Participants were in 52 federally funded treatment programs that administered four 
types of treatment modalities: methadone maintenance, therapeutic communities, outpatient 
drug-free treatment, and detoxification. Conducted by researchers at Texas Christian 
University, data were collected through client interviews with treated clients and persons 
who applied for treatment but never returned for services (intake-only clients). Information 
was also collected from clients' progress reports and other program records. Follow-up 
intervals occurred from 3 to 12 years after treatment. “The DARP findings have been widely 
used to support continued public funding of drug-abuse treatments and to influence federal 
drug policy in the United States” (DARP, 2007, p.3) 
DARP found that clients’ daily use of opiates declined from 100 percent prior to treatment to 
36 percent in the first year after treatment and to 24 percent 3 years after treatment. In the 
DARP study, addicts who were in treatment for more than 90 days were significantly less 
likely to use drugs in the year after treatment than those who were in treatment for fewer 
than 90 days (Simpson & Sells, 1982). Outpatient drug-free treatment, methadone 
maintenance, and therapeutic communities were equally effective at producing positive 
outcomes; clients in detoxification programs or those who dropped out of treatment within 
3 months showed no positive outcomes. Moreover, among drug treatment clients in general, 
arrest rates declined 74 percent and employment rates increased 24 percent after treatment. 
Twelve years after treatment, daily heroin use remained 74 percent lower (Simpson, 1993; 
Simpson & Sells, 1982, 1990). 
Approximately three-fourths of the opiate addicts studied in DARP reported at least one 
relapse to daily use after they had experienced a period of sobriety. The highest percentage 
of addicts (85%) who quit using drugs, did so while in treatment. The most common reasons 
reported for staying sober referred primarily to the adverse consequences of addiction. For 
example, 83 percent of the treatment participants indicated that they quit because they were 
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“tired of the hustle,” 56 percent, because they were “afraid of going to jail,” and 54 percent, 
because they had to “meet family responsibilities” (Simpson & Sells, 1990).     
10.2 Treatment outcome prospective study 
TOPS involved 11,000 people admitted from 1979 through 1981 to 41 drug treatment 
programs in 10 cities. Three types of programs were examined—outpatient drug free, 
residential, and methadone maintenance—and clients were followed 1, 2, and 3 to 5 years 
after treatment. TOPS found that drug treatment reduced drug use for as many as 5 years 
after a single treatment episode; different treatment modalities appeared to be equally 
effective in helping drug users recover. Declines in drug use were most dramatic among 
heroin and cocaine users (Hubbard et al., 1989) 
TOPS also produced solid evidence that drug treatment reduces drug users' criminal 
activities. Three to 5 years after treatment, the proportion of clients engaged in pretreatment 
predatory crimes decreased by one-third to one-half among the three treatment modalities. 
Moreover, TOPS demonstrated that drug treatment is cost-effective and cost-beneficial; data 
showed that the costs of treatment were recouped largely during treatment and that 
additional cost savings accrued with reductions in post-treatment drug use. Criminal justice 
savings were significant. Researchers reported a 30 percent decline in costs to victims of 
drug-related crimes and a 24 percent decline in costs to the criminal justice system 
(Harwood, Collins, Hubbard, Marsden, & Rachal, 1988). TOPS' principal investigators, 
Hubbard et al. (1989), concluded that "publicly funded drug abuse treatment is essential to 
our national effort to reduce the demand for drugs and its related social and economic costs" 
(p. 12) 
10.3 Drug abuse treatment outcome study 
DATOS, the third NIDA-funded comprehensive evaluation of drug abuse treatment 
(Leshner, 1997), followed a sample of 10,000 clients in 96 programs located in 11 large- and 
medium-sized cities in the United States for 36 months, from 1991 through 1993. DATOS 
participants were selected from four treatment programs: outpatient drug-free, outpatient 
methadone maintenance, short-term inpatient, and long-term residential. According to 
Leshner (1997), DATOS was “the first national study of treatment outcomes since the AIDS 
epidemic began, the first to examine outcomes for community-based cocaine abuse 
treatment, the first since the transition to NIDA block grants in 1981, and the first to include 
public and private short-term inpatient hospitals as a treatment modality” (p. 211) (also see 
Hubbard, Craddock, Flynn, Anderson, & Etheridge, 1997). 
DATOS found that a larger percentage of drug-free outpatients than similar TOPS 
participants were involved in the criminal justice system and that clients with psychiatric 
disorders were more likely to be poly-drug users (Flynn, Craddock, Luckey, Hubbard, & 
Dunteman, 1996). Drug treatment significantly reduced drug use from pretreatment 
baseline levels to 12-month post-treatment levels for persons addicted to heroin, cocaine, 
and other types of drugs (Hubbard, et al., 1997; Simpson, Brown, & Joe 1997). DATOS also 
found that ancillary services for addicts had declined, but drug treatment programs were 
delivering core services (i.e., assessment, treatment, and aftercare) more effectively than they 
had in the DARP and TOPS studies (Etheridge, Hubbard, Anderson, Craddock, & Flynn, 
1997). 
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In a five-year study of cocaine addicts, DATOS researchers reported that treatment reduced 
cocaine use from 100 percent at intake to 25 percent 5 years after discharge from treatment. 
Illegal activity declined from 40 percent in year 1 post-treatment to 25 percent in year 5 post-
treatment. In general, the study found that clients with more serious drug and psychosocial 
problems at intake had poorer outcomes in treatment. However, more exposure to 
treatment was related to more positive long-term outcomes (Simpson, Brown, & Joe, 1997). 
11. National treatment improvement evaluation study   
Another federally funded, national evaluation of drug treatment was the National 
Treatment Improvement Evaluation Study (NTIES). Funded by the Center for Substance 
Abuse Treatment and conducted by the National Opinion Research Center and the Research 
Triangle Institute, NTIES used a highly rigorous methodology and extensive outcome 
measures. The purpose of the project was to investigate the impact of drug treatment on 
more than 4,000 clients in publicly supported drug treatment programs across the country.   
NTIES found that drug treatment had numerous favorable effects on clients, including 
reductions in drug use. For example, one year after treatment, clients’ use of heroin dropped 
from 73 to 38 percent while cocaine use dropped from 40 to 18 percent. The study also found 
post-treatment reductions in arrests rates, self-reported criminal activities, drug selling, and 
illegal earnings. Among treatment participants, homelessness, unemployment, and welfare 
dependency declined while overall physical and mental health problems became less severe. 
Moreover, participants engaged in safer sex practices after drug treatment than before; 
specifically, the percentage of participants who reported having sex for money declined 56 
percent, and the number who had sex with an intravenous drug user declined 51 percent 
(Substance Abuse and Mental Health Services Administration [SAMHSA], 2007).    
12. Services research outcome study 
The Services Research Outcome Study (SROS), conducted by the Substance Abuse and 
Mental Health Services Administration (SAMHSA), was the first nationally representative 
study of drug treatment in the United States. SROS involved 1,800 participants in inpatient, 
outpatient, and residential care who were discharged in 1990 from a random sample of 100 
facilities in rural, suburban, and urban areas nationwide. Five years after treatment, 
participants were interviewed; the results showed consistent reductions in drug use —
namely, 45 percent in cocaine use, 28 percent in marijuana use, 17 percent in crack cocaine 
use, and 14 percent in alcohol and heroin use. The study also reported 23 to 38 percent 
reductions in criminal activity, such as burglary, the selling of drugs, and prostitution. 
Finally, after completing drug treatment, participants were less likely to be involved in 
physically abusive relationships or to attempt suicide and were more likely to live in secure 
housing (SAMHSA, 1998). 
13. Principles of effective drug treatment 
Several basic principles underlie and characterize successful drug treatment practices. These 
principles have largely been derived from studies of whether and how drug treatment 
works to change addicts’ behaviors; many of these studies were discussed earlier in this 
chapter (Anglin et al., 1996, 1998; Prendergast, Anglin, & Wellisch, 1995; Taxman & Spinner, 
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1997). With funding and guidance from NIDA, researchers explored the implementation of 
drug treatment programs and their effects on a variety of populations. Their aggregate 
findings led to the identification of core program elements that assist addicts in achieving 
sobriety and improving their lives in many areas of functioning (NIDA, 2006a; 2006b). The 
following is a synthesis and distillation of NIDA’s principles of effective drug-treatment 
programs.     
13.1 Drug assessment and treatment matching  
The first principle is that no single drug treatment regimen is useful for all addicts (NIDA, 
2006a). To develop successful treatment approaches, tailored to each client’s addiction and 
service needs, clinical evaluations must be conducted to assess the specific nature and extent 
of clients’ substance use disorders. The fundamental clinical question is what type of 
treatment or intervention is most appropriate for what type of client, in which type of 
setting, and for what length of time (NIDA, 2006a.  
A crucial first step in the formulation of an individualized treatment plan is the use of 
comprehensive and standardized assessment protocols that collect accurate information 
about a client’s current and previous drug use; criminal history; medical conditions; drug 
and psychiatric treatment experiences; education and employment records; cognitive, 
psychological, and interpersonal adjustment; and social support networks (Anglin et al., 
1996). Before treatment begins, a client’s readiness and motivation for change must also be 
thoroughly evaluated (NIDA, 1999).  
At intake, clients should be tested for communicable diseases (e.g., HIV/AIDS, tuberculosis, 
and Hepatitis B and C), which are significantly more prevalent among people who use 
drugs (NIDA, 2006a). If they test positive, clients should be counseled on treatment options 
and the importance of avoiding behaviors that can spread infections to others. If they test 
negative, clients should be counseled on ways to prevent infection through safer sex and 
drug-use practices (so-called harm reduction strategies) as they strive for recovery.        
Following assessment, clients’ problems and needs should be matched to treatment settings 
and strategies (NIDA, 2006a). Addicts who openly acknowledge their drug problems and 
commit fully to the recovery process can benefit greatly from drug treatment and adjunctive 
social and medical services (Simpson, 1998b). Repeated, unfavorable consequences from 
substance abuse can lead addicts to realize that professional interventions are necessary to 
achieve sobriety (Hoffman & Fromeke, 2007). Thus, addicts with extensive drug use and 
criminal histories are often amenable to treatment (Anglin et al., 1996).  
Clients in the early stages of drug use can also be excellent candidates for drug treatment 
programs (Center for Substance Abuse Treatment, 1994). With the implementation of proper 
assessment and treatment-matching techniques, most persons with substance use disorders 
can be helped by treatment at any juncture in their addiction careers. The old adage that 
drug abusers must “hit rock bottom” before they can begin recovery is supported by neither 
research nor clinical experience (Hoffman & Fromeke, 2007). 
13.2 Availability and length of participation  
The second principle is that effective treatment takes time and must be highly accessible and 
readily available to take advantage of addicts’ readiness for change (NIDA, 2006a). People 
with substance use disorders can lose their interest and willingness to enter treatment when 
they languish on waiting lists for services. Drug users must break through their denial and 
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hesitancy and become motivated in the early stages of the recovery process, paving the way 
for long-term care (Anglin et al., 1996). Motivational interviewing techniques can be quite 
effective in encouraging engagement in the initial phases of treatment (NIDA, 2006a).  
Treatment takes time.  Addiction is an intractable disease and cannot be overcome with brief 
interventions. Hence, the goal of treatment should be the management of addiction, not its 
cure. Many studies show that the length of stay in treatment is positively related to 
outcomes (De Leon, 1991; Simpson, 1979, 1998a; Simpson, Joe, Lehman, & Sells, 1986). 
However, clients frequently leave drug treatment prematurely; therefore, different strategies 
must be used to engage and retain addicts in services long enough for them to gain 
therapeutic benefit from their participation. The threshold for achieving significant 
improvement in treatment is generally reached in three months, and several episodes of 
treatment, aftercare, and relapse are expected before abstinence is attained (Gendreau, 1996; 
Wexler, Falkin, Lipton, & Rosenblum, 1992).  
Fletcher, Tims, and Brown (1997) observed that the "association between treatment duration 
and outcomes is strong enough to warrant research simply to improve retention.” 
Furthermore, they stated that "time itself is a surrogate measure that might represent, for 
example, motivation, willingness to adhere to treatment, a process of behavioral change, or 
the ability of the practitioner to engage the patient" (p. 223). Therefore, favorable treatment 
outcomes depend not only on time spent in treatment but also on what happens during 
treatment to change clients' behaviors (Anglin et al., 1996). Recovery is a nonlinear process. 
Addicts learn to eschew old patterns of thinking (e.g., criminogenic attitudes and beliefs) 
and behaving and to replace them with new problem-solving skills for reducing cravings, 
avoiding relapse triggers (i.e., places, persons, and paraphernalia that remind the addict of 
drug use), and re-establishing healthy interpersonal relationships. Recovery involves steady 
progress toward a responsible, abstinent, and productive life (NIDA, 2006a).  
13.3 Treatment structure and coercion  
The third principle is that treatment should be both highly structured and adaptable, 
involving medical detoxification for persons with a substance dependence disorder and a 
contingency management component for all clients. Detoxification safely alleviates the acute 
physical symptoms of withdrawal and is a necessary (but not sufficient) precursor to 
successful drug treatment. Under a physician’s care, detoxification is conducted in a hospital 
or residential setting and lasts from three to five days (Hoffman & Fromeke, 2007; NIDA, 
2006a). After a client becomes stabilized through detoxification, progressive incentives can 
be incorporated into treatment. Different types of contingency contracts include positive and 
negative reinforcements to encourage addicts to remain drug free and engaged in the 
therapeutic process (Onken, Blain, & Boren, 1997). Voucher-based incentives can be 
combined with non-monetary rewards, such as verbal recognition, reward ceremonies, and 
certificates of completion (NIDA, 2006a).  
Graduated sanctions should be leveled against participants who do not adhere to program 
regulations, and rewards should be given to those who do. To be most effective, positive 
and negative sanctions must be clearly specified, explicitly tied to behaviors, and swiftly 
administered (NIDA, 2006a). They should also be progressive and commensurate with the 
severity of clients’ rule breaking or their degree of improvement. Clients should be 
monitored throughout treatment to overcome their struggles to identify and avoid the 
triggers for relapse. The continued use of drugs should be tracked through urinalysis or 
other objective drug tests (NIDA, 2006a).    
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Treatment success depends on the adaptability of services in meeting addicts’ changing life 
circumstances (McLellan, Arndt, Metzger, Woody, & O'Brien, 1993). Interventions are most 
effective when they are responsive to addicts' evolving needs at different points in the 
recovery process (Anglin et al., 1996). Treatment and service plans should be continually 
renewed and modified throughout recovery. They must always be sensitive and responsive 
to differences in clients’ age, gender, race, ethnicity, and sexual orientation. Practitioners 
should be skilled at combining several modalities, including medication, individual and 
group psychotherapy, family interventions, childcare assistance, and legal services.  
Medications, such as methadone, LAAM, Naltrexone, and bupropion, can be essential 
aspects of care, especially when administered with psychotherapy and other supportive 
interventions (NIDA, 2006a). In addition, “self help can complement and extend the effects 
of professional treatment” (NIDA, 2006a, p. 20). Self-help interventions include 12-step 
programs (e.g., Alcoholics Anonymous, Narcotics Anonymous, and Cocaine Anonymous) 
(NIDA, 2006a).  
Drug treatment programs must be flexible in their responses to relapses—expected, not 
exceptional, setbacks on the pathway to sobriety. Relapses can occur even after prolonged 
periods of abstinence, although addicts are most vulnerable to relapse in the first three to six 
months after treatment (Hoffman & Fromeke, 2007; NIDA, 2006a). Occasional drug use by 
participants, which minimally disrupts the recovery process, should be handled 
immediately through placement in detoxification, exposure to graduated sanctions, or 
return to a higher level of care. As a rule, one or two minor relapses should not result in 
participants being summarily dropped from drug treatment programs as the termination of 
treatment after relapse is ill-advised, unjustified, and unethical from a medical standpoint 
(Hoffman & Fromeke, 2007).  
Addicts who are coerced into drug treatment by legal mandates are just as successful in 
recovery as those who enter treatment programs voluntarily, and legally coerced 
participants typically remain in treatment programs longer (Anglin et al., 1990). Whenever 
possible, legal mandates should be used to order offenders to participate in drug treatment 
programs and to hold them accountable for their progress in recovery (NIDA, 2006a). 
Coercion involves entering and complying with drug treatment or facing legal 
consequences. Participation is mandatory and noncompliance can result in sanctions, such 
as incarceration, the loss of child custody rights, or more stringent conditions of community 
supervision. Coerced treatment can be mandated at various stages of the criminal justice 
process and imposed with varying degrees of restrictiveness. Judges can offer a defendant 
the choice between treatment and incarceration. Probation officers can recommend and 
enforce treatment as a court-ordered condition of probation. Prison administrators can place 
inmates involuntarily into drug treatment programs (Lurigio, 2002).  
A willingness to enter treatment is not a prerequisite for success (Hoffman & Fromeke, 
2007). Legal coercion compels addicts make decisions that they might not be able to make on 
their own. Coercion is leverage that keeps addicted offenders in treatment long enough to 
benefit from the positive effects of a supportive therapeutic experience and become 
intrinsically motivated to remain and succeed in care. In short, coerced treatment provides 
services for addicts that would otherwise have been unavailable to them (Lurigio, 2002).  
13.4 Evidence-based treatment    
The fourth principle is that drug treatment must be evidence-based (science-validated) and 
implemented in accordance with proven models of recovery (Hoffman & Fromeke, 2007). 
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Evidence-based practices are never grounded in a drug treatment agency’s traditions or the 
experiences or preferences of its staff; instead, they are supported by independent research 
that demonstrates their effectiveness in achieving outcomes that are broadly endorsed by 
experts and practitioners in the addiction field (Lurigio, 2006). As Brady states in Hoffman 
and Fromeke (2007, p. 135), “Evidence-based treatment is treatment that has been proven to 
work through rigorous scientific studies. Evidence-based treatment is particularly important 
in the addictions field because many myths and personal biases have infiltrated the 
treatment area and are often accepted without question.”   
The most compelling evidence of a program’s effectiveness emerges from research that 
includes representative samples of participants, random assignment to treatment and 
control groups, and baseline and follow-up measures of client performance that are valid 
(accurate) and reliable (consistent). Moreover, the most useful results of studies—for the 
purpose of establishing evidence-based practices—are based on evaluations of programs 
that are manualized and implemented by trained, credentialed, and experienced staff 
persons. Practitioners must implement treatment protocols carefully and consistently, and 
participate regularly in professional development activities (Lurigio, 2006). Evidence-based 
drug treatment services include: relapse prevention therapy, supportive-expressive 
psychotherapy, individualized drug counseling, motivational enhancement therapy, 
multidimensional family therapy for adolescents, and the matrix model (NIDA 2006b).  
13.5 Network of services  
The fifth principle is that people with substance use problems should receive services that 
address their other difficulties (NIDA, 2006a). Drug abusers tend to suffer from a variety of 
psychological, medical, and social problems as well as deficits in education, employment, 
and housing (Swartz & Lurigio, 1999). Many of these problems persist throughout the 
recovery process (McLellan, et al., 1981). Drug treatment practitioners should collaborate 
with other service providers (e.g., psychiatrists and psychologists, vocational training 
experts, and housing advocates) in addressing the multifaceted problems of drug addicts, 
especially those with comorbid psychiatric disorders who need integrated substance use 
and psychiatric treatment services. Addicts must be treated comprehensively; their various 
problems should be addressed simultaneously, not sequentially (Waller & Weiner, 1989). 
13.6 Continuity of care   
The sixth principle is that residential (short- or long-term) treatment must be followed by a 
continuum of care, namely, intensive outpatient treatment, aftercare, and relapse prevention 
services. Seamless interventions are instrumental in achieving sobriety (NIDA, 2006a; 
Russell, 1994). As mentioned throughout this chapter, drug abuse and dependence disorders 
are chronic, and several cycles of treatment and aftercare services—often “with a cumulative 
impact”—are required to minimize relapses and sustain recovery (NIDA, 1999, p. 16). If 
drug abusers remain in intensive treatment for at least 90 days and receive continuous care 
after treatment, they are more likely to attain sobriety, get a job, and stop committing crimes 
(NIDA, 2006b).  
Continuity of care is particularly crucial to the recovery of drug-involved offenders leaving 
correctional settings (NIDA, 1999; Peters, 1993). Offenders who complete structured drug 
treatment programs in jails or prisons should be assisted in their transition to community-
based services by engaging in prerelease planning and programming activities. Without 
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aftercare services (i.e., continuity of care), the gains that offenders make in prison or jail 
treatment programs are frequently diminished or lost altogether (Lipton, 1995; NIDA, 
2006a).  
Prison inmates who participated in a drug treatment program with follow-up services in 
work release centers demonstrated significantly lower drug use and recidivism rates than 
those who participated in institutional treatment only (Inciardi, 1998). Similarly, offenders 
participating in both prison- and community-based treatment programs were less likely to 
commit subsequent crimes than offenders who participated in drug treatment without 
follow-up care (Wexler, 1996; Wexler, De Leon, Thomas, Kressel, & Peters, 1999). 
Numerous obstacles can impede the delivery of aftercare services, including the fragmented 
nature of the criminal justice system, the lack of coordination between criminal justice 
practitioners and treatment providers, and the absence of incentives and sanctions for 
offenders to remain drug free after unsupervised release from jails and prisons. The paucity 
of community treatment programs and treatment providers' inexperience with offenders are 
also impediments to recovery (Field, 1998). Relapse prevention services for offenders should 
be more thoroughly studied and understood (Vigdal, 1995) as suggested by the following 
under-investigated and unresolved issues: 
 Reasons why offenders are especially vulnerable to relapse, including stressors related 
to release from correctional facilities and psychosocial factors related to crime and drug 
use; 
 The evolving recovery process at its various stages; 
 The destabilized and stabilized relapse-prone individual; 
 Methods to overcome recovery plateaus; 
 Basic components of relapse prevention therapy (e.g., self-knowledge and identification 
of warning signs, coping skills and management of warning signs, and involvement of 
family members and others in the relapse prevention plan; and 
 The timing of relapse prevention efforts, particularly in advance of release from jail and 
prison. 
13.7 Service coordination   
The seventh principle is that drug treatment programs for offenders work best when 
criminal justice professionals (e.g., probation, parole, and detention officers) and service 
providers communicate with one another and coordinate their efforts (NIDA, 2006a). Cross-
training can help both groups understand the competencies and limitations of the other and 
work more effectively as a case management team. As stated in NIDA (2006a), “The 
coordination of drug abuse treatment with correctional planning can encourage 
participation in drug abuse treatment and can help treatment providers incorporate 
correctional requirements as treatment goals.” (p. 3)   
Treatment Alternatives for Safe Communities (TASC) was the culmination of a federal effort 
to establish and promote coordination between criminal justice agencies and treatment 
providers at the local level. Seeded in 1972 with funding from the Law Enforcement and 
Assistance Administration, TASC’s first pilot program was implemented in Wilmington, 
Delaware. By 2007, more than 220 TASC programs were operating in 30 states. TASC 
identifies, assesses, and refers offenders at the pretrial and post-adjudication levels to 
treatment and adjunctive services. TASC monitors clients' treatment progress through case 
management, urine testing, and other techniques, and reports violations of the conditions of 
release to the court.  
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Case managers establish linkages between treatment providers and correctional staff in 
order to develop coordinated strategies that hold offenders accountable and protect 
community safety (Anglin et al., 1996; Inciardi & McBride, 1991; Swartz, 1993; Weinman, 
1990). The critical elements of TASC operations include “a process to coordinate justice, 
treatment, and other systems; procedures for providing information and cross-training to 
justice, treatment, and other systems; policies and procedures for regular staff training; 
clearly defined client eligibility criteria; and performance of client-centered case 
management” (National TASC, 2007).    
13.8 Program evaluation   
The eighth principle is that drug treatment programs should be routinely examined by 
outside evaluators to determine whether services are being implemented as planned 
(treatment fidelity) and to measure the overall impact of services (treatment effectiveness). 
Process evaluations should provide program staff members with real-time information that 
can be used to improve service delivery and preserve treatment integrity. Outcome 
evaluations should be based on internally valid research designs that incorporate random 
assignment and control groups; such designs yield data that permit confident conclusions 
about program effectiveness. Researchers should also consider client selection criteria and 
attrition (i.e., program dropouts) when interpreting results. 
Evaluations of program impact must include a variety of outcome measures, such as 
number and type of drugs used; frequency of drug use; treatment retention; desistence from 
criminal activities; length of time to relapse and rearrest; vocational skills; employment; 
social, psychological, and family functioning; reliance on social service agencies; physical 
and emotional health; HIV risk behaviors; and mortality rates (Anglin & Hser, 1990; Swartz, 
1993; Vigdal, 1995). Finally, researchers should test different treatment modalities to 
ascertain which approaches work best with which groups of clients; they should also 
employ longitudinal and nested research designs to understand more precisely the 
effectiveness of interventions as well as the trajectories of participants' addiction and 
criminal careers (Leukefeld & Tims, 1992).  
14. Conclusions  
The use of illicit substances is common in the United States. The casual use of drugs can 
escalate to misuse, abuse, and dependence, resulting in distress and impairment in 
functioning as well as hardship for users’ families and the larger community. The criteria for 
rendering a clinical diagnosis of drug abuse and dependence are enumerated in the 4th 
Edition of the Diagnostic and Statistical Manual of the American Psychiatric Association 
(DSM-IV-TR). These criteria help diagnosticians in evaluating the nature and severity of 
substance use disorders. Although substance use disorders produce serious harm for those 
affiliated with such problems, they are considered treatable conditions. Many studies have 
demonstrated the effectiveness of drug treatment in leading to recovery. Substance use 
changes brain chemistry and functioning; therefore addiction is a chronic disease that 
requires a life-long commitment to achieve long-term sobriety. 
Since the War on Drugs was declared 40 years ago, people arrested for drug crimes have 
been the fastest-growing subpopulations at every step in the criminal justice process from 
arrest to post-incarcerative release from prison. The criminal justice system often provides 
www.intechopen.com
 
Psychiatric Disorders – Trends and Developments 
 
334 
the first and only opportunity for criminally involved drugs users to obtain substance abuse 
treatment and other recovery services. NIDA has discussed several principles of effective 
care for drug-involved members of the general and correctional populations, including 
assessment, treatment matching, relapse prevention, the use of medications and adjunctive 
services, and the evaluation of services to identify evidence-based practices.        
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